Literature DB >> 31498486

MicroRNA-96 is a potential tumor repressor by inhibiting NPTX2 in renal cell carcinoma.

Wei Xiang1, Lintao Han2, Guoyan Mo2, Li Lin1, Xiaoming Yu1, Shaowen Chen1, Tiexiang Gao1, Chunhua Huang1.   

Abstract

MicroRNA-96 (miR-96) is a vertebrate conserved microRNA which plays important roles in various cancers including renal cell carcinoma (RCC). However, its function and mechanism in RCC are still unclear. In this study, miR-96 was found to be downregulated in RCC based on The Cancer Genome Atlas datasets analyses, and its target genes, which predicted by TargetScan, were investigated. Among these target genes, neuronal pentraxin 2 (NPTX2) was upregulated more than 15-fold in RCC, and moreover, closely related to patient survival. To validate its targeting of NPTX2 experimentally, reverse transcription polymerase chain reaction, Western blot analysis, and dual-luciferase assays were performed, and results of these assays demonstrated that miR-96 inhibited expression of NPTX2 through a single 3'-untranslated region targeting site. Furthermore, transfection assays in RenCa and 786-O cells showed miR-96 and small interfering RNA of NPTX2 inhibited cell proliferation, migration, and invasion and overexpression of NPTX2 recovered the inhibition of miR-96. In conclusion, the present study reveals a novel regulatory mechanism of miR-96 on NPTX2 expression in RCC, and the potential of miR-96 as a RCC tumor repressor deserves further investigation.
© 2019 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31498486     DOI: 10.1002/jcb.29385

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  8 in total

Review 1.  MicroRNA-96: A therapeutic and diagnostic tumor marker.

Authors:  Hamid Reza Rahimi; Majid Mojarrad; Meysam Moghbeli
Journal:  Iran J Basic Med Sci       Date:  2022-01       Impact factor: 2.532

2.  [MicroRNA-145-5p over-expression suppresses proliferation, migration and invasion and promotes apoptosis of human endometrial cancer cells by targeting dual specific phosphatase 6].

Authors:  Yingchao Men; Lei Zhang; Hao Ai
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2020-01-30

3.  Overexpression of NPTX2 Promotes Malignant Phenotype of Epithelial Ovarian Carcinoma via IL6-JAK2/STAT3 Signaling Pathway Under Hypoxia.

Authors:  Xiaotian Han; Yechen Lu; Xiaoqi Li; Lingfang Xia; Hao Wen; Zheng Feng; Xingzhu Ju; Xiaojun Chen; Xiaohua Wu
Journal:  Front Oncol       Date:  2021-03-09       Impact factor: 6.244

4.  miR-96-5p targets PTEN to mediate sunitinib resistance in clear cell renal cell carcinoma.

Authors:  Sang Eun Park; Wonju Kim; Ji-Ye Hong; Dayeon Kang; Seulki Park; Jungyo Suh; Dalsan You; Yun-Yong Park; Nayoung Suh; Jung Jin Hwang; Choung-Soo Kim
Journal:  Sci Rep       Date:  2022-03-03       Impact factor: 4.379

5.  miR-1251-5p Overexpression Inhibits Proliferation, Migration, and Immune Escape in Clear Cell Renal Cell Carcinoma by Targeting NPTX2.

Authors:  Lin Yue; Hualong Lin; Shaofei Yuan; Lili Wu; Guangming Chen; Jiaqi Wang; Jieni Feng
Journal:  J Oncol       Date:  2022-03-10       Impact factor: 4.375

6.  Sevoflurane alleviates hepatic ischaemia/reperfusion injury by up-regulating miR-96 and down-regulating FOXO4.

Authors:  Binghua He; Fan Yang; Yingxia Ning; Yalan Li
Journal:  J Cell Mol Med       Date:  2021-06-01       Impact factor: 5.310

7.  Promoter Methylation-Mediated NPTX2 Silencing Promotes Tumor Growth in Human Prostate Cancer.

Authors:  Yixi Su; Qiang Huang; Li Lu; Hu Qu; Dejuan Wang; Jianguang Qiu; Weiqian Li; Mengmeng Lin; Huanliang Liu; Zhongyang Wang; Xiangling Yang
Journal:  J Cancer       Date:  2022-01-01       Impact factor: 4.207

8.  Silencing circular RNA circ_0054537 and upregulating microRNA-640 suppress malignant progression of renal cell carcinoma via regulating neuronal pentraxin-2 (NPTX2).

Authors:  Long Pei; Xianqiang Lv; Gaopei Jia; Xiaoliang Tan; Ming Li; Aili Zhang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.